Adverts

Open Access Articles- Top Results for Ecromeximab

Ecromeximab

</th></tr>
Ecromeximab?
Monoclonal antibody
Type Whole antibody
Source Chimeric (mouse/human)
Target GD3 ganglioside
Clinical data
Identifiers
292819-64-8 7pxN
None
UNII M76FX2JZRM 7pxY
Chemical data
145,255 Daltons
 14pxN (what is this?)  (verify)

Ecromeximab is a chimeric monoclonal antibody being developed for the treatment of malignant melanoma.[1][2]

This drug was developed by Kyowa Hakko Kogyo Co., Ltd.

References

  1. Statement On A Nonproprietary Name Adopted By The USAN Council - Ecromeximab, American Medical Association.
  2. Clinical trial number NCT00679289 for "Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Cutaneous Melanoma" at ClinicalTrials.gov


Lua error in package.lua at line 80: module 'Module:Buffer' not found. Lua error in package.lua at line 80: module 'Module:Buffer' not found.